# Semaglutide

> Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, for chronic weight management. It is one of the most extensively studied agents in this class, with multiple large randomized trials documenting its effects on body weight and glycemic control. It is administered by once-weekly subcutaneous injection, with an oral daily tablet formulation available for diabetes indications. Individual responses vary, and it is intended for use alongside lifestyle modification under medical supervision.

- URL: https://www.lifeconverted.com/peptides/semaglutide
- Also known as: Ozempic, Wegovy, Rybelsus
- Primary category: Weight Management
- Effectiveness rank: #5 in Weight Management
- Evidence level: Well studied
- Route: Subcutaneous (An oral tablet formulation (Rybelsus) is approved for diabetes and dosed daily; the subcutaneous formulation is the form most studied and approved for weight management.)
- Dose range: 0.25-2.4 mg
- Dose tiers: low 0.25 mg; moderate 1 mg; high 2.4 mg
- Half-life: Approximately 7 days (168 hours), supporting once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous, ongoing use with titration per prescriber guidance on, Not typically cycled off; discontinuation should be discussed with a prescriber off (Weight regain has been documented in follow-up studies after stopping treatment.)
- Storage: Refrigerate at 2-8°C; pens may be kept at room temperature for a limited period per manufacturer labeling; protect from light and do not freeze.

## Mechanism of action

Semaglutide mimics the endogenous incretin hormone GLP-1, activating GLP-1 receptors in the pancreas, gut, and brain. This slows gastric emptying, increases feelings of fullness, and reduces appetite signaling in the hypothalamus, while also enhancing glucose-dependent insulin secretion.

## Reported benefits

- Associated with significant average body-weight reduction in clinical trials
- Improves glycemic control in type 2 diabetes
- May reduce certain cardiovascular risk markers in studied populations
- Once-weekly injection schedule with an oral alternative for diabetes

## Reported side effects

- Nausea, vomiting, diarrhea, and constipation, especially during titration
- Decreased appetite
- Risk of gallbladder-related events
- Injection-site reactions
- Labeled theoretical thyroid C-cell tumor risk based on animal studies

## Common protocols

- Manufacturer-labeled step-up titration every 4 weeks
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

Combining with other GLP-1 agents is not supported by evidence; combination with agents acting on different pathways (e.g., amylin analogs) has been studied in trials but should only occur under medical supervision.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer